The US Food and Drug Administration (FDA) has granted approval for the blood-based companion diagnostic test for TAGRISSO (osimertinib).

Roche-developed, cobas EGFR Mutation Test v2 examines either a tissue or a blood sample to confirm the presence of a T790M mutation in patients exhibiting metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), which has progressed on or after administration of an EGFR tyrosine kinase inhibitor (TKI) medicine.

It serves as a non-invasive option suitable for NSCLC patients who may not be suitable for biopsy procedures.

"This development offers an important option for the identification of the T790M mutation in patients with metastatic EGFR mutation-positive NSCLC."

Patients testing negative for the T790M mutation with blood-based test are made to undergo the tissue-based testing to confirm the presence of EGFR T790M mutation.

AstraZeneca oncology US medical affairs vice-president Andrew Coop said: “The availability of an FDA-approved, blood-based companion diagnostic is a tremendous step forward for patients with lung cancer in need of a high-quality test that provides results with a rapid turnaround time.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This development offers an important option for the identification of the T790M mutation in patients with metastatic EGFR mutation-positive NSCLC who have progressed on an EGFR TKI medicine, for whom a tissue biopsy may not be feasible.

"Delivering targeted therapies, such as TAGRISSO, to the right patients at the right time demonstrates our commitment to testing and quality companion diagnostics."